BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 23782249)

  • 1. Standards in molecular diagnostics for the discovery and validation of clinically useful cancer biomarkers.
    Vydelingum NA; Sorbara L; Wagner P; Srivastava S
    Expert Rev Mol Diagn; 2013 Jun; 13(5):421-3. PubMed ID: 23782249
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AACR-FDA-NCI cancer biomarkers collaborative.
    Yu LR; Veenstra TD
    Expert Rev Mol Diagn; 2007 Sep; 7(5):507-9. PubMed ID: 17892359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Strategic approach to validating methylated genes as biomarkers for breast cancer.
    Wang W; Srivastava S
    Cancer Prev Res (Phila); 2010 Jan; 3(1):16-24. PubMed ID: 20051369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular testing in oncology: problems, pitfalls and progress.
    O'Brien CP; Taylor SE; O'Leary JJ; Finn SP
    Lung Cancer; 2014 Mar; 83(3):309-15. PubMed ID: 24472389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Personalized oncology: recent advances and future challenges.
    Kalia M
    Metabolism; 2013 Jan; 62 Suppl 1():S11-4. PubMed ID: 22999010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AACR-FDA-NCI Cancer Biomarkers Collaborative consensus report: advancing the use of biomarkers in cancer drug development.
    Khleif SN; Doroshow JH; Hait WN;
    Clin Cancer Res; 2010 Jul; 16(13):3299-318. PubMed ID: 20501613
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bioinformatics: biomarkers of early detection.
    Crichton DJ; Mattmann CA; Thornquist M; Anton K; Hughes JS
    Cancer Biomark; 2010; 9(1-6):511-30. PubMed ID: 22112493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Diagnostic kits in parasitology: which controls?].
    Rossi P
    Parassitologia; 2004 Jun; 46(1-2):145-9. PubMed ID: 15305705
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Translational crossroads for biomarkers.
    Bast RC; Lilja H; Urban N; Rimm DL; Fritsche H; Gray J; Veltri R; Klee G; Allen A; Kim N; Gutman S; Rubin MA; Hruszkewycz A
    Clin Cancer Res; 2005 Sep; 11(17):6103-8. PubMed ID: 16144908
    [TBL] [Abstract][Full Text] [Related]  

  • 10. US FDA perspective on challenges in co-developing in vitro companion diagnostics and targeted cancer therapeutics.
    Philip R; Carrington L; Chan M
    Bioanalysis; 2011 Feb; 3(4):383-9. PubMed ID: 21338257
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigenetic biomarkers in laboratory diagnostics: emerging approaches and opportunities.
    Sandoval J; Peiró-Chova L; Pallardó FV; García-Giménez JL
    Expert Rev Mol Diagn; 2013 Jun; 13(5):457-71. PubMed ID: 23782253
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology.
    Tahara H; Sato M; Thurin M; Wang E; Butterfield LH; Disis ML; Fox BA; Lee PP; Khleif SN; Wigginton JM; Ambs S; Akutsu Y; Chaussabel D; Doki Y; Eremin O; Fridman WH; Hirohashi Y; Imai K; Jacobson J; Jinushi M; Kanamoto A; Kashani-Sabet M; Kato K; Kawakami Y; Kirkwood JM; Kleen TO; Lehmann PV; Liotta L; Lotze MT; Maio M; Malyguine A; Masucci G; Matsubara H; Mayrand-Chung S; Nakamura K; Nishikawa H; Palucka AK; Petricoin EF; Pos Z; Ribas A; Rivoltini L; Sato N; Shiku H; Slingluff CL; Streicher H; Stroncek DF; Takeuchi H; Toyota M; Wada H; Wu X; Wulfkuhle J; Yaguchi T; Zeskind B; Zhao Y; Zocca MB; Marincola FM
    J Transl Med; 2009 Jun; 7():45. PubMed ID: 19534815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proceedings of the Second Workshop on Theory meets Industry (Erwin-Schrödinger-Institute (ESI), Vienna, Austria, 12-14 June 2007).
    Hafner J
    J Phys Condens Matter; 2008 Feb; 20(6):060301. PubMed ID: 21693862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Role of the surgical pathology laboratory in the pre-analytical approach of molecular biology techniques].
    Hofman V; Ilie M; Gavric-Tanga V; Lespinet V; Mari M; Lassalle S; Butori C; Coelle C; Bordone O; Selva E; Lamy A; Sabourin JC; Hofman P
    Ann Pathol; 2010 Apr; 30(2):85-93. PubMed ID: 20451063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An overview of the optimal planning, design, and conduct of phase I studies of new therapeutics.
    LoRusso PM; Boerner SA; Seymour L
    Clin Cancer Res; 2010 Mar; 16(6):1710-8. PubMed ID: 20215546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bioinformatics strategies for translating genome-wide expression analyses into clinically useful cancer markers.
    Rhodes DR; Chinnaiyan AM
    Ann N Y Acad Sci; 2004 May; 1020():32-40. PubMed ID: 15208181
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The NCI All Ireland Cancer Conference.
    Johnston PG; Daly PA; Liu E
    Oncologist; 1999; 4(4):275-277. PubMed ID: 10545862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trends in biomarker research for cancer detection.
    Srinivas PR; Kramer BS; Srivastava S
    Lancet Oncol; 2001 Nov; 2(11):698-704. PubMed ID: 11902541
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Joint National Cancer Institute-Food and Drug Administration workshop on research strategies, study designs, and statistical approaches to biomarker validation for cancer diagnosis and detection.
    Maruvada P; Srivastava S
    Cancer Epidemiol Biomarkers Prev; 2006 Jun; 15(6):1078-82. PubMed ID: 16775163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New science-based endpoints to accelerate oncology drug development.
    Kelloff GJ; Sigman CC
    Eur J Cancer; 2005 Mar; 41(4):491-501. PubMed ID: 15737552
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.